GHRH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-25. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
=== Compounds with the group 13 elements === The intermetallic compounds of the alkali metals with the heavier group 13 elements (aluminium, gallium, indium, and thallium), such as NaTl, are poor conductors or semiconductors, unlike the normal alloys with the preceding elements, implying that the alkali metal involved has lost an electron to the Zintl anions involved. Nevertheless, while the elements in group 14 and beyond tend to form discrete anionic clusters, group 13 elements tend to form polymeric ions with the alkali metal cations located between the giant ionic lattice. For example, NaTl consists of a polymeric anion (—Tl−—)n with a covalent diamond cubic structure with Na+ ions located between the anionic lattice. The larger alkali metals cannot fit similarly into an anionic lattice and tend to force the heavier group 13 elements to form anionic clusters. Boron is a special case, being the only nonmetal in group 13. The alkali metal borides tend to be boron-rich, involving appreciable boron–boron bonding involving deltahedral structures, and are thermally unstable due to the alkali metals having a very high vapour pressure at elevated temperatures. This makes direct synthesis problematic because the alkali metals do not react with boron below 700 °C, and thus this must be accomplished in sealed containers with the alkali metal in excess.
British importer BBH Spirits began to import Hill's Absinth from the Czech Republic in the 1990s, as the UK had never formally banned it, and this sparked a modern resurgence in its popularity. It began to reappear during a revival in the 1990s in countries where it was never banned. Forms of absinthe available during that time consisted almost exclusively of Czech, Spanish, and Portuguese brands that were of recent origin, typically consisting of Bohemian-style products. Connoisseurs considered these of inferior quality and not representative of the 19th-century spirit. In 2000, La Fée Absinthe became the first commercial absinthe distilled and bottled in France since the 1914 ban, but it is now one of dozens of brands that are produced and sold within France. In the Netherlands, the restrictions were challenged by Amsterdam wine seller Menno Boorsma in July 2004, thus confirming the legality of absinthe once again. Similarly, Belgium lifted its long-standing ban on 1 January 2005 citing a conflict with the adopted food and beverage regulations of the single European Market. In Switzerland, the constitutional ban was repealed in 2000 during an overhaul of the national constitution although the prohibition was written into ordinary law instead. That law was later repealed, and absinthe was made legal on March 1, 2005. The drink was never officially banned in Spain although it began to fall out of favour in the 1940s and almost vanished into obscurity. Catalonia has seen a significant resurgence since 2007 when one producer established operations there.
Hops are the female flower clusters or seed cones of the hop vine Humulus lupulus, which are used as a flavouring and preservative agent in nearly all beer made today. Hops had been used for medicinal and food flavouring purposes since Roman times; by the 7th century in Carolingian monasteries in what is now Germany, beer was being made with hops, though it isn't until the thirteenth century that widespread cultivation of hops for use in beer is recorded. Before the thirteenth century, beer was flavoured with plants such as yarrow, wild rosemary, and bog myrtle, and other ingredients such as juniper berries, aniseed and ginger, which would be combined into a mixture known as gruit and used as hops are now used; between the thirteenth and the sixteenth century, during which hops took over as the dominant flavouring, beer flavoured with gruit was known as ale, while beer flavoured with hops was known as beer. Some beers today, such as Fraoch by the Scottish Williams Bros Brewing Company and Cervoise Lancelot by the French Brasserie Lancelot, use plants other than hops for flavouring. Hops contain several characteristics that brewers desire in beer: they contribute a bitterness that balances the sweetness of the malt; they provide floral, citrus, and herbal aromas and flavours; they have an antibiotic effect that favours the activity of brewer's yeast over less desirable microorganisms; and they aid in "head retention", the length of time that the foam on top of the beer (the beer head) will last.
=== Functionalization === Many properties of nanoparticles, notably stability, solubility, and chemical or biological activity, can be radically altered by coating them with various substances — a process called functionalization. Functionalized nanomaterial-based catalysts can be used for catalysis of many known organic reactions. For example, suspensions of graphene particles can be stabilized by functionalization with gallic acid groups. For biological applications, the surface coating should be polar to give high aqueous solubility and prevent nanoparticle aggregation. In serum or on the cell surface, highly charged coatings promote non-specific binding, whereas polyethylene glycol linked to terminal hydroxyl or methoxy groups repel non-specific interactions. By the immobilization of thiol groups on the surface of nanoparticles or by coating them with thiomers high (muco)adhesive and cellular uptake enhancing properties can be introduced. Nanoparticles can be linked to biological molecules that can act as address tags, directing them to specific sites within the body specific organelles within the cell, or causing them to follow specifically the movement of individual protein or RNA molecules in living cells. Common address tags are monoclonal antibodies, aptamers, streptavidin, or peptides. These targeting agents should ideally be covalently linked to the nanoparticle and should be present in a controlled number per nanoparticle.
Sources: en.wikipedia.org
Gordon R. Ward, writing in the correspondence columns of the British Medical Journal, proposed the use of blood plasma as a substitute for whole blood and for transfusion purposes as early as 1918. At the onset of World War II, liquid plasma was used in Britain. A large project, known as "Blood for Britain", began in August 1940 to collect blood in New York City hospitals for the export of plasma to Britain. Following heavy casualties in the Battle of Dunkirk, the Blood Transfusion Association in New York City originated the campaign that was enlarged to the whole US by the Red Cross, and was called the National Blood Programme. At the time, American physician Edwin Cohn pioneered the process of blood fractionation. He worked out the techniques for isolating the serum albumin fraction of blood plasma, which is essential for maintaining the osmotic pressure in the blood vessels, preventing their collapse. A freeze-dried plasma package was developed by the Surgeons General of the Army and Navy, working with the National Research Council, which reduced breakage and made transportation, packaging, and storage much simpler.
Gastrointestinal problems can be part of CMT, as can difficulty chewing, swallowing, and speaking (due to atrophy of vocal cords). A tremor can develop as muscles waste. Pregnancy has been known to exacerbate CMT, as well as severe emotional stress. Patients with CMT must avoid periods of prolonged immobility, such as when recovering from a secondary injury, as prolonged periods of limited mobility can drastically accelerate symptoms of CMT. Pain is a common symptom experienced by individuals with Charcot–Marie–Tooth disease, often resulting from postural abnormalities, skeletal deformities, muscle fatigue, and cramping. This pain can typically be managed through a combination of physical therapy, orthopedic interventions, and the use of corrective or assistive devices. In cases where these approaches do not provide sufficient relief, analgesic medications may be necessary to alleviate discomfort and improve quality of life. Although the disease is typically slowly progressive and not life-threatening, the degree of disability can vary. Some people may live relatively normal lives with mild symptoms, while others may require orthopedic supports, physical therapy, or even surgery to manage complications. The variation in symptoms and severity is influenced by the specific genetic mutation causing the condition. While some genes are linked to earlier onset and more severe forms of CMT, others result in milder forms with slower progression. Furthermore, even when the same gene is involved, the symptoms can differ between individuals.
On 14 May 2026, nine TTP militants and four military personnel were killed in a skirmish following an insurgent attack on Mena Army camp in Bajaur District. Militants attacked and killed an ambulance driver in Bannu. Aircraft activity and drones were reported over Kabul in the morning, followed by two large explosions and gunfire. On 15 May 2026, further drone activity, anti-aircraft fire and explosions were reported in Kabul, for the second consecutive night. On 16 May 2026, five militants including two commanders were killed under Operation Intiqam-e-Shuhada in retaliation for the suicide bombing targeting police, the week prior. On 18 May 2026, two policemen deployed to protect polio vaccination teams were killed by militants in Bajaur District. On 19 May 2026, Pakistan's Prime Minister Shahbaz Sharif reiterated that Operation Ghazab lil-Haq is "continuing with full resolve" and would remain continued, against Afghan Taliban regime and it's terrorist proxies, continuing to target their hideouts and infrastructure. After the statement, Pakistani forces conducted a clearance operation in Shewa, North Waziristan killing 22 TTP militants. Meanwhile, a policeman and a Federal Constabulary personnel were killed in separate attacks in Dera Ismail Khan and Tank districts. On 21 May 2026, two children were killed in a quadcopter strike in Bajaur District. Five TTP militants including a commander were killed by Pakistani forces in an operation in North Waziristan. On 22 May 2026, 19 JuA and 3 TTP militants were killed in interjihadist violence in Kurram District.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.